JP2022546985A - 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物 - Google Patents

非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物 Download PDF

Info

Publication number
JP2022546985A
JP2022546985A JP2022513552A JP2022513552A JP2022546985A JP 2022546985 A JP2022546985 A JP 2022546985A JP 2022513552 A JP2022513552 A JP 2022513552A JP 2022513552 A JP2022513552 A JP 2022513552A JP 2022546985 A JP2022546985 A JP 2022546985A
Authority
JP
Japan
Prior art keywords
oncolytic virus
transport inhibitor
nucleocytoplasmic transport
cancer
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546985A5 (enExample
Inventor
グラント マクファデン，ダグラス
マスムズール ラフマーン，モハメド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona State University Downtown Phoenix campus
Original Assignee
Arizona State University Downtown Phoenix campus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona State University Downtown Phoenix campus filed Critical Arizona State University Downtown Phoenix campus
Publication of JP2022546985A publication Critical patent/JP2022546985A/ja
Publication of JP2022546985A5 publication Critical patent/JP2022546985A5/ja
Priority to JP2024192261A priority Critical patent/JP2025028853A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022513552A 2019-09-02 2020-09-01 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物 Pending JP2022546985A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192261A JP2025028853A (ja) 2019-09-02 2024-10-31 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962894929P 2019-09-02 2019-09-02
US62/894,929 2019-09-02
US201962913667P 2019-10-10 2019-10-10
US62/913,667 2019-10-10
PCT/US2020/048932 WO2021046048A1 (en) 2019-09-02 2020-09-01 Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192261A Division JP2025028853A (ja) 2019-09-02 2024-10-31 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物

Publications (2)

Publication Number Publication Date
JP2022546985A true JP2022546985A (ja) 2022-11-10
JP2022546985A5 JP2022546985A5 (enExample) 2023-09-08

Family

ID=74853433

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513552A Pending JP2022546985A (ja) 2019-09-02 2020-09-01 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物
JP2024192261A Pending JP2025028853A (ja) 2019-09-02 2024-10-31 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192261A Pending JP2025028853A (ja) 2019-09-02 2024-10-31 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物

Country Status (9)

Country Link
US (1) US12691151B2 (enExample)
EP (1) EP4025230B1 (enExample)
JP (2) JP2022546985A (enExample)
KR (1) KR20220054865A (enExample)
CN (1) CN114667154A (enExample)
AU (1) AU2020340934A1 (enExample)
CA (1) CA3152787A1 (enExample)
IL (1) IL290974A (enExample)
WO (1) WO2021046048A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
CN116077505B (zh) * 2023-01-17 2024-09-06 广东省人民医院 Kpt-330联合5-fu或奥沙利铂在抗胃癌肿瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531739A (ja) * 2005-03-07 2008-08-14 ロバーツ リサーチ インスティテュート 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431349A1 (en) 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
WO2004015118A1 (en) 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531739A (ja) * 2005-03-07 2008-08-14 ロバーツ リサーチ インスティテュート 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUM GEN THER., vol. 23, JPN6024030879, 2012, pages 1003 - 15, ISSN: 0005384316 *
J BIOL CHEM., vol. 281, no. 11, JPN6024030877, 2016, pages 7357 - 7363, ISSN: 0005521951 *
NEURO ONCOL., vol. 15, no. 7, JPN6024030878, 2013, pages 904 - 20, ISSN: 0005384315 *

Also Published As

Publication number Publication date
WO2021046048A1 (en) 2021-03-11
AU2020340934A1 (en) 2022-03-31
EP4025230A4 (en) 2023-10-04
JP2025028853A (ja) 2025-03-05
CA3152787A1 (en) 2021-03-11
US12691151B2 (en) 2026-07-28
KR20220054865A (ko) 2022-05-03
EP4025230B1 (en) 2025-11-05
IL290974A (en) 2022-05-01
EP4025230A1 (en) 2022-07-13
US20220296660A1 (en) 2022-09-22
CN114667154A (zh) 2022-06-24

Similar Documents

Publication Publication Date Title
EP4025230B1 (en) Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
US9987315B2 (en) Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
CN106265679A (zh) 溴结构域蛋白抑制剂在制备抗hiv-1潜伏治疗药物中的用途
Wu et al. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting
AU2004216928A1 (en) Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US20090137661A1 (en) Plant derived compounds and compound formulae containing the same for the treatment of cervical cancer
US12398375B2 (en) Methods for improved poxvirus yields
HK40076417A (en) Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
US20250387443A1 (en) Enhancing oncolytic virotherapy with a combination of nuclear export inhibitor and myxoma virus activating cell death pathways
WO2023192955A2 (en) Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus
CN115778952A (zh) 番木瓜生物碱在制备抗新冠病毒的药物中的应用
US11591616B1 (en) Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC
Topno et al. Efficacy of antibiotics (doxycycline and kanamycin) against Japanese encephalitis virus infection
Holechek Lessons from Vaccinia Virus Post-Exposure Prophylaxis: Insights into Control of Diseases and Epidemics
Liu et al. Oleanolic Acid (Oa) Anti-Nnv is Achieved by Inhibiting Nnv-Induced Apoptosis and Enhancing Innate Immunity
HK1163175B (en) Use of a myxoma virus that does not express functional m135r for therapeutic treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221024

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250205